Effect of enterally administered sleep-promoting medication on the intravenous sedative dose and its safety and cost profile in mechanically ventilated patients: a retrospective cohort study
- Conditions
- critical ill patients
- Registration Number
- JPRN-UMIN000043475
- Lead Sponsor
- Department of Emergency and Critical Care Medicine, Hyogo Prefectural Amagasaki General Medical Center
- Brief Summary
The average daily propofol dose per body weight administered as a continuous sedative during mechanical ventilation through an oral endotracheal tube was significantly lower in the early administration group (EA group) than in the late administration (LA group) and no administration group (NA group) (Beta Coefficient -5.18 [95% CI -8.95 to -1.40], Beta Coefficient -4.51 [95% CI -8.58 to -0.44]); however, there was no difference between the LA and NA groups (Beta Coefficient 0.66 [95% CI -3.14 to 4.46]).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 123
Not provided
central nervous system disease (stroke, epilepsy, meningitis, encephalitis, etc.), cardiopulmonary arrest, traumatic brain injury, overdose, gastrointestinal tract impracticability (administration of continuous neuromuscular blockade, abdominal surgery, ileus, gastrointestinal bleeding, etc.), previous psychiatric or cognitive pathology, Child C hepatopathy, pregnancy, previous tracheostomy, ICU readmission, lacking body weight records, death in ICU, and not receiving propofol.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The average daily propofol dose per body weight administered as a continuous sedative during mechanical ventilation through an oral endotracheal tube.
- Secondary Outcome Measures
Name Time Method